Meng Yuan

Epitope-focused S2 stem-helix nanoparticle immunogens elicit protective broadly neutralizing antibodies against diverse betacoronaviruses in non-human primates, establishing a framework for pan-betacoronavirus vaccines.

This paper describes the directed evolution of an antibody to enhance its binding affinity for MERS-CoV, resulting in cross-neutralization against multiple betacoronaviruses.

This study identifies a cross-reactive germline antibody that can be evolved to neutralize multiple SARS-CoV-2 variants through targeted somatic mutations.

This study identifies an immunodominant S2 apex epitope in SARS-CoV-2 that elicits a public antibody clonotype, highlighting its role as a barrier to universal coronavirus vaccines.

This study vaccinates nonhuman primates with SARS-CoV-2 and MERS-CoV spike proteins to elicit cross-reactive antibodies that neutralize both sarbecoviruses and merbecoviruses.

This paper describes VYD222, a broadly neutralizing antibody effective against SARS-CoV-2 variants, including Omicron, and explains its structural basis for resistance to viral escape.

This paper reports structural analysis of VRC01-class bnAb precursors from a vaccine trial, showing they bind HIV Env with germline-like features and glycan adaptability.

This study shows that CR3022-like antibodies can be evolved in vivo through vaccination to neutralize SARS-CoV-2 and related viruses by enhancing affinity and breadth.

The paper examines how mutations and a deletion in the KP.3.1.1 SARS-CoV-2 spike protein affect ACE2 binding and antibody escape, revealing structural and functional insights into its evolution.

This study identifies a camelid single-domain antibody that allosterically inhibits trypanosomatid pyruvate kinases, reducing parasite growth.